Gefitinib or erlotinib for previously treated lung adenocarcinoma

Which is superior?

Chia Hao Chang, Chih Hsin Lee, Jann Yuan Wang

Research output: Contribution to journalLetter

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)1374
Number of pages1
JournalJournal of Clinical Oncology
Volume35
Issue number12
DOIs
Publication statusPublished - Apr 20 2017

Fingerprint

Erlotinib Hydrochloride
Adenocarcinoma of lung
gefitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gefitinib or erlotinib for previously treated lung adenocarcinoma : Which is superior? / Chang, Chia Hao; Lee, Chih Hsin; Wang, Jann Yuan.

In: Journal of Clinical Oncology, Vol. 35, No. 12, 20.04.2017, p. 1374.

Research output: Contribution to journalLetter

@article{9df17019506343d7a5021c65e9c83525,
title = "Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?",
author = "Chang, {Chia Hao} and Lee, {Chih Hsin} and Wang, {Jann Yuan}",
year = "2017",
month = "4",
day = "20",
doi = "10.1200/JCO.2016.68.5842",
language = "English",
volume = "35",
pages = "1374",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Gefitinib or erlotinib for previously treated lung adenocarcinoma

T2 - Which is superior?

AU - Chang, Chia Hao

AU - Lee, Chih Hsin

AU - Wang, Jann Yuan

PY - 2017/4/20

Y1 - 2017/4/20

UR - http://www.scopus.com/inward/record.url?scp=85017648983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017648983&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.68.5842

DO - 10.1200/JCO.2016.68.5842

M3 - Letter

VL - 35

SP - 1374

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -